First, the predictive value of PD-L1 as a vital biomarker is affected by its detection methods, including diverse immunohistochemistry platforms and antibodies, variant sample sources (archived or fresh specimens) and handing procedures (timing), and different types of cells assessed (tumor or immune cells). This evidence concerns the gene CD274 and neoplasm.